Ohio State star Caleb Downs didn't test at the NFL Combine, but rumors are circulating that two major knee issues were ...

The current development of AI and ASI carries a catastrophic systemic risk, with industry insiders estimating a 10 to 25 ...

Evan Soltas and Jonathan Gruber have published a paper titled, “How Costly Is Permitting in Housing Development?”. They ...

Pope Leo XIV is not a Luddite. Late at night, when the silence of the Apostolic Palace feels a bit too heavy, he fires up ...

Behind last week’s scrum between the Trump administration and Anthropic lies a deeper question of how warfare is ...

India ranks sixth in global IP filings, with over 55% from residents. But filing is only the start. As global capital demands enforceable, portable IP, early governance will determine long-term ...

AMT-130 Huntington’s gene therapy data, FDA Phase III sham-trial push, cash runway, and 2026 catalysts—read now.

The transformation of prudential data is rapidly becoming one of the most significant structural changes in banking supervision. In recent years, the Bank of England (BoE) and the Prudential ...

After 9 months of unrelenting gains, the market did the unthinkable - it declined in value. Sentiment around the AI stocks that have fanned the flames of this bull market dimmed this month.

Source: Even an amateur can drill a borehole; so what is so special to justify a term extension? This would have been a joke, had it not been so tragic. Tendai Ruben Mbofana ​The political atmosphere ...

I've realized that the number one recommendation I can make is the one many Americans overlook: hiring a mountain guide. I've got no skin in the game. I'm not a guide, just an American skier in love ...

Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for ...